Browse > Article
http://dx.doi.org/10.1038/s12276-018-0184-0

FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of β-catenin  

Liang, Tao (Department of Urology, Shanghai Sixth People's Hospital East Affiliated to Shanghai University of Medicine & Health Sciences)
Ye, Xuxiao (Department of Urology, Shanghai Sixth People's Hospital East Affiliated to Shanghai University of Medicine & Health Sciences)
Liu, Yuanyuan (Department of Urology, Affiliated Hospital of Binzhou Medical University)
Qiu, Xinkai (Department of Urology, Affiliated Hospital of Binzhou Medical University)
Li, Zuowei (Department of Urology, Shanghai Sixth People's Hospital East Affiliated to Shanghai University of Medicine & Health Sciences)
Tian, Binqiang (Department of Urology, Shanghai Sixth People's Hospital East Affiliated to Shanghai University of Medicine & Health Sciences)
Yan, Dongliang (Department of Urology, Shanghai Sixth People's Hospital East Affiliated to Shanghai University of Medicine & Health Sciences)
Publication Information
Experimental and Molecular Medicine / v.50, no.12, 2018 , pp. 8.1-8.12 More about this Journal
Abstract
FAM46B is a member of the family with sequence similarity 46. Little is known about the expression and functional role (s) of FAM46B in prostate cancer (PC). In this study, the expression of FAM46B expression in The Cancer Genome Atlas, GSE55945, and an independent hospital database was measured by bioinformatics and real-time PCR analysis. After PC cells were transfected with siRNA or a recombinant vector in the absence or presence of a ${\beta}$-catenin signaling inhibitor (XAV-939), the expression levels of FAM46B, C-myc, Cyclin D1, and ${\beta}$-catenin were measured by western blot and realtime PCR. Cell cycle progression and cell proliferation were measured by flow cytometry and the CCK-8 assay. The effects of FAM46B on tumor growth and protein expression in nude mice with PC tumor xenografts were also measured. Our results showed that FAM46B was downregulated but that ${\beta}$-catenin was upregulated in patients with PC. FAM46B silencing promoted cell proliferation and cell cycle progression in PC, which were abrogated by XAV-939. Moreover, FAM46B overexpression inhibited PC cell cycle progression and cell proliferation in vitro and tumor growth in vivo. FAM46B silencing promoted ${\beta}$-catenin protein expression through the inhibition of ${\beta}$-catenin ubiquitination. Our data clearly show that FAM46B inhibits cell proliferation and cell cycle progression in PC through ubiquitination of ${\beta}$-catenin.
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Center, M. M. et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012).   DOI
2 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).   DOI
3 Wen, S., Niu, Y., Lee, S. O. & Chang, C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat. Rev. 40, 31-40 (2014).   DOI
4 Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015).   DOI
5 Ozdemir, T. R. et al. Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia. Urol. Oncol. 35, 607.e15-607.e24 (2017).   DOI
6 Etokebe, G. E. et al. Association of the FAM46A gene VNTRs and BAG6 rs3117582 SNP with non small cell lung cancer (NSCLC) in Croatian and Norwegian populations. PLoS ONE 10, e0122651 (2015).   DOI
7 Deng, Z. et al. Identification of novel susceptibility markers for the risk of overall breast cancer as well as subtypes defined by hormone receptor status in the Chinese population. J. Hum. Genet 61, 1027-1034 (2016).   DOI
8 Zhang, Q. Y., Yue, X.Q., Jiang, Y. P., Han, T. & Xin, H. L. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells. Sci. Rep. 7, 396 (2017).   DOI
9 Mroczek, S. et al. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Nat. Commun. 8, 619 v (2017).   DOI
10 Zhu, Y. X. et al. Loss of FAM46C promotes cell survival in myeloma. Cancer Res. 77, 4317-4327 (2017).   DOI
11 Faramarzi, S. & Ghafouri-Fard, S. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy. Immunotherapy 9, 1019-1034 (2017).   DOI
12 Zhao, Y. et al. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation. Oncol. Rep. 38, 3055-3063 (2017).   DOI
13 Kuehl, W. M. & Bergsagel, P. L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122, 3456-3463 (2012).   DOI
14 Benjachat, T. et al. Biomarkers for refractory lupus nephritis: a microarray study of kidney tissue. Int J. Mol. Sci. 16, 14276-14290 (2015).   DOI
15 Chen, Y. & Song, W. Wnt/catenin beta1/microRNA 183 predicts recurrence and prognosis of patients with colorectal cancer. Oncol. Lett. 15, 4451-4456 (2018).
16 Wan, X. Y. et al. Antimetastatic effects of norcantharidin on hepatocellular carcinoma cells by up-regulating FAM46C expression. Am. J. Transl. Res. 9, 155-166 (2017).
17 Li, Y. H. et al. Mefloquine targets beta-catenin pathway and thus can play a role in the treatment of liver cancer. Microb. Pathog. 118, 357-360 (2018).   DOI
18 Yang, Y. et al. Downregulation of miR-3127-5p promotes epithelialmesenchymal transition via FZD4 regulation of Wnt/beta-catenin signaling in non-small-cell lung cancer. Mol. Carcinog. 57, 842-853 (2018).   DOI
19 Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012).   DOI
20 Zhang, J. Q. et al. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/betacatenin signaling pathway by targeting CUL4B in pancreatic cancer cells. J. Cell Biochem 119, 1027-1040 (2018).   DOI
21 Jamieson, C., Sharma, M. & Henderson, B. R. Wnt signaling from membrane to nucleus: beta-catenin caught in a loop. Int J. Biochem Cell Biol. 44, 847-850 (2012).   DOI
22 Liu, H. et al. CSN5 promotes hepatocellular carcinoma progression by SCARA5 inhibition through Suppressing beta-catenin ubiquitination. Dig. Dis. Sci. 63, 155-165 (2018).   DOI
23 Novellasdemunt, L. et al. USP7 is a tumor-specific WNT activator for APCmutated colorectal cancer by mediating beta-catenin deubiquitination. Cell Rep. 21, 612-627 (2017).   DOI
24 Higashimori, A. et al. Forkhead box F2 suppresses gastric cancer through a novel FOXF2-IRF2BPL-beta-catenin signaling axis. Cancer Res. 78, 1643-1656 (2018).   DOI
25 Cordonnier, T. et al. Hsp27 regulates EGF/beta-catenin mediated epithelial to mesenchymal transition in prostate cancer. Int J. Cancer 136, E496-E507 (2015).   DOI
26 Xu, X. et al. Expression of a novel gene FAM43B repressing cell proliferation is regulated by DNA methylation in hepatocellular carcinoma cell lines. Mol. Cell Biochem. 354, 11-20 (2011).   DOI
27 Xie, H. et al. Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells. BMB Rep. 47, 104-109 (2014).   DOI
28 Miliani de Marval, P. L. et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol. Cell Biol. 24, 7538-7547 (2004).   DOI
29 Bertoli, C., Skotheim, J. M. & de Bruin, R. A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518-528 (2013).   DOI
30 Pascual, A. & Aranda, A. Thyroid hormone receptors, cell growth and differentiation. Biochim. Biophys. Acta 1830, 3908-3916 (2013).   DOI
31 Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (2007).   DOI
32 Chu, I. et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128, 281-294 (2007).   DOI
33 Yin, H. et al. Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclin D1 and MMP-7. Oncol. Rep. 37, 1045-1051 (2017).   DOI
34 Mahoney, S., Arfuso, F., Millward, M. & Dharmarajan, A. The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. Cancer Cell Int. 14, 110 (2014).   DOI
35 Martino, T. et al. The pterocarpanquinone LQB-118 inhibits tumor cell proliferation by downregulation of c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle inhibitor expression. Bioorg. Med. Chem. 22, 3115-3122 (2014).   DOI
36 Wang, D., Lu, G., Shao, Y. & Xu, D. MiR-182 promotes prostate cancer progression through activating Wnt/beta-catenin signal pathway. Biomed. Pharmacother. 99, 334-339 (2018).   DOI
37 Rubin, S. M. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem. Sci. 38, 12-19 (2013).   DOI
38 Gough, N. R. Focus issue: Wnt and beta-catenin signaling in development and disease. Sci. Signal. 5, eg2 (2012).